Compare TransMedics Group Inc (TMDX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Growth Index Fund ETF — how do they compare? TransMedics Group Inc trades at $74.3 (market cap $2.54B), while Vanguard Growth Index Fund ETF trades at $86.16. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VUG | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $150.42 | $90.29 |
52-Week Low | $61.99 | $70.00 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
VUG trades at $85.32, up 0.06% with a bearish technical signal from moving averages. The ETF's low expense ratio of 0.03% and strong historical returns, including a 411% total return over the past decade per The Motley Fool (2026-07-12), highlight its cost efficiency. Recent news emphasizes its growth focus and tech-heavy holdings, with a stock split executed on 21 April 2026. Support levels are clustered around $84-$85, indicating potential near-term stability.
Outlook remains positive for long-term investors due to VUG's low-cost structure and exposure to high-growth U.S. large-cap stocks. Risks include high concentration in technology sectors and market volatility. Analyst sentiment is generally favorable, supporting a buy-and-hold strategy for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
